272 related articles for article (PubMed ID: 32076642)
1. Coupling Cas9 to artificial inhibitory domains enhances CRISPR-Cas9 target specificity.
Aschenbrenner S; Kallenberger SM; Hoffmann MD; Huck A; Eils R; Niopek D
Sci Adv; 2020 Feb; 6(6):eaay0187. PubMed ID: 32076642
[TBL] [Abstract][Full Text] [Related]
2. Cell-specific CRISPR-Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins.
Hoffmann MD; Aschenbrenner S; Grosse S; Rapti K; Domenger C; Fakhiri J; Mastel M; Börner K; Eils R; Grimm D; Niopek D
Nucleic Acids Res; 2019 Jul; 47(13):e75. PubMed ID: 30982889
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-based epigenome editing: An overview of dCas9-based tools with special emphasis on off-target activity.
Tadić V; Josipović G; Zoldoš V; Vojta A
Methods; 2019 Jul; 164-165():109-119. PubMed ID: 31071448
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas gene therapy.
Zhang B
J Cell Physiol; 2021 Apr; 236(4):2459-2481. PubMed ID: 32959897
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-mediated genome editing of splicing mutation causing congenital hearing loss.
Ryu N; Kim MA; Choi DG; Kim YR; Sonn JK; Lee KY; Kim UK
Gene; 2019 Jun; 703():83-90. PubMed ID: 30898719
[TBL] [Abstract][Full Text] [Related]
6.
Acharya S; Mishra A; Paul D; Ansari AH; Azhar M; Kumar M; Rauthan R; Sharma N; Aich M; Sinha D; Sharma S; Jain S; Ray A; Jain S; Ramalingam S; Maiti S; Chakraborty D
Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20959-20968. PubMed ID: 31570623
[TBL] [Abstract][Full Text] [Related]
7. Recruitment of DNA Repair MRN Complex by Intrinsically Disordered Protein Domain Fused to Cas9 Improves Efficiency of CRISPR-Mediated Genome Editing.
Reuven N; Adler J; Broennimann K; Myers N; Shaul Y
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31597252
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in CRISPR/Cas9-Mediated Genome Editing in
Muramoto T; Iriki H; Watanabe J; Kawata T
Cells; 2019 Jan; 8(1):. PubMed ID: 30642074
[TBL] [Abstract][Full Text] [Related]
9. Anti-CRISPR AcrIIA5 Potently Inhibits All Cas9 Homologs Used for Genome Editing.
Garcia B; Lee J; Edraki A; Hidalgo-Reyes Y; Erwood S; Mir A; Trost CN; Seroussi U; Stanley SY; Cohn RD; Claycomb JM; Sontheimer EJ; Maxwell KL; Davidson AR
Cell Rep; 2019 Nov; 29(7):1739-1746.e5. PubMed ID: 31722192
[TBL] [Abstract][Full Text] [Related]
10. A compact Cas9 ortholog from Staphylococcus Auricularis (SauriCas9) expands the DNA targeting scope.
Hu Z; Wang S; Zhang C; Gao N; Li M; Wang D; Wang D; Liu D; Liu H; Ong SG; Wang H; Wang Y
PLoS Biol; 2020 Mar; 18(3):e3000686. PubMed ID: 32226015
[TBL] [Abstract][Full Text] [Related]
11. Improving CRISPR-Cas9 Genome Editing Efficiency by Fusion with Chromatin-Modulating Peptides.
Ding X; Seebeck T; Feng Y; Jiang Y; Davis GD; Chen F
CRISPR J; 2019 Feb; 2():51-63. PubMed ID: 31021236
[TBL] [Abstract][Full Text] [Related]
12. Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants.
Walton RT; Christie KA; Whittaker MN; Kleinstiver BP
Science; 2020 Apr; 368(6488):290-296. PubMed ID: 32217751
[TBL] [Abstract][Full Text] [Related]
13. Sharpening the Scissors: Mechanistic Details of CRISPR/Cas9 Improve Functional Understanding and Inspire Future Research.
Raper AT; Stephenson AA; Suo Z
J Am Chem Soc; 2018 Sep; 140(36):11142-11152. PubMed ID: 30160947
[TBL] [Abstract][Full Text] [Related]
14. Potent Cas9 Inhibition in Bacterial and Human Cells by AcrIIC4 and AcrIIC5 Anti-CRISPR Proteins.
Lee J; Mir A; Edraki A; Garcia B; Amrani N; Lou HE; Gainetdinov I; Pawluk A; Ibraheim R; Gao XD; Liu P; Davidson AR; Maxwell KL; Sontheimer EJ
mBio; 2018 Dec; 9(6):. PubMed ID: 30514786
[TBL] [Abstract][Full Text] [Related]
15. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
16. Synthetic switch to minimize CRISPR off-target effects by self-restricting Cas9 transcription and translation.
Shen CC; Hsu MN; Chang CW; Lin MW; Hwu JR; Tu Y; Hu YC
Nucleic Acids Res; 2019 Feb; 47(3):e13. PubMed ID: 30462300
[TBL] [Abstract][Full Text] [Related]
17. Cas9 deactivation with photocleavable guide RNAs.
Zou RS; Liu Y; Wu B; Ha T
Mol Cell; 2021 Apr; 81(7):1553-1565.e8. PubMed ID: 33662274
[TBL] [Abstract][Full Text] [Related]
18. Harnessing CRISPR/Cas9 technology in cardiovascular disease.
Rezaei H; Khadempar S; Farahani N; Hosseingholi EZ; Hayat SMG; Sathyapalan T; Sahebkar AH
Trends Cardiovasc Med; 2020 Feb; 30(2):93-101. PubMed ID: 30935726
[TBL] [Abstract][Full Text] [Related]
19. Rationally engineered
Tan Y; Chu AHY; Bao S; Hoang DA; Kebede FT; Xiong W; Ji M; Shi J; Zheng Z
Proc Natl Acad Sci U S A; 2019 Oct; 116(42):20969-20976. PubMed ID: 31570596
[TBL] [Abstract][Full Text] [Related]
20. Scaffold-mediated non-viral delivery platform for CRISPR/Cas9-based genome editing.
Chin JS; Chooi WH; Wang H; Ong W; Leong KW; Chew SY
Acta Biomater; 2019 May; 90():60-70. PubMed ID: 30978509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
